Intensity Modulated Radiotherapy Market Revenue to Attain USD 5.10 Bn by 2035

Published: 24 Mar 2026

Author: Precedence Research

Share:

Intensity Modulated Radiotherapy Market Revenue and Trends 2026 to 2035

The global intensity modulated radiotherapy market revenue surpassed USD 2.71 billion in 2025 and is predicted to attain around USD 5.10 billion by 2035, growing at a CAGR of 6.52%. The intensity-modulated radiotherapy market is driven by the rising prevalence of cancer and increasing adoption of advanced radiation therapy technologies that enable precise tumor targeting while minimizing damage to surrounding healthy tissues.

What Drives the Intensity Modulated Radiotherapy Market?

The intensity modulated radiotherapy market is driven by the growing use of AI-based treatment planning, improving precision and efficiency in radiation therapy. The market is also driven by the need for real-time tumor monitoring, which supports accurate dose delivery while protecting healthy tissues. Advancements in linear accelerators enhance treatment speed and workflow, while rising cancer cases and the shift toward personalized, patient-centric therapy further boost demand for targeted radiotherapy.

Segment Insights

• By IMRT delivery technique type, the volumetric modulated arc therapy segment dominated the market in 2025, due to its ability to deliver precise radiation doses in shorter treatment times. Improved beam control and integration with advanced planning and image-guided systems have increased its use in treating cancers such as prostate, head and neck, and brain tumors.
• By system component type, the linear accelerator system segment dominated the market in 2025, as it serves as the primary component for delivering high-energy radiation beams in IMRT treatments. Advanced systems enable precise tumor targeting while protecting healthy tissue, and their adoption is increasing with rising cancer cases and growing investments in oncology care.
• By cancer site case, the prostate cancer segment registered dominance in the market, holding the largest share in 2025, because of the high prevalence of prostate cancer around the world. The need for precise radiation delivery near sensitive organs like the bladder and rectum, where Intensity-Modulated Radiotherapy enables targeted high-dose treatment while minimizing damage to surrounding tissues.
• By end user case, the hospitals segment held the largest market share in 2025, driven by advanced infrastructure, specialized oncology departments, and skilled multidisciplinary teams, making hospitals the primary centers for complex treatments like Intensity-Modulated Radiotherapy and handling a large volume of cancer patients.
• By service model type, the new system installation segment maintains its dominance in the market, holding a major revenue share in 2025. This is because healthcare providers’ preference for installing new Intensity-Modulated Radiotherapy systems with advanced linear accelerators, AI-based planning, and image-guided technologies, supported by rising investments in cancer care infrastructure and expanding oncology facilities.

Regional Insights

North America dominated the intensity modulated radiotherapy market by holding the largest share of 36.70% in 2025. This dominance is driven by the availability of advanced imaging technologies, high healthcare spending, and the rapid adoption of new cancer treatments. The region boasts well-developed oncology and radiotherapy centers that enable precise therapies like Intensity-Modulated Radiotherapy amid rising cases of prostate, breast, and brain cancers.

Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period. This growth is driven by rising cancer cases and expanding healthcare infrastructure in countries such as China, India, Japan, and South Korea, along with increasing adoption of advanced radiotherapy technologies like Intensity-Modulated Radiotherapy, supported by better awareness, insurance coverage, and growing oncology facilities.

Intensity Modulated Radiotherapy Market Coverage

Recent Developments

• On Jan 20, 2026, a phase III trial by the University of Texas MD Anderson Cancer Center, reported in The Lancet, found that Intensity Modulated Proton Therapy (IMPT) was noninferior to Intensity Modulated Radiation Therapy (IMRT) in progression-free survival for oropharyngeal cancer, with improved overall survival and lower high-grade toxicity.(Source: https://ascopost.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8121

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344